Alignment Healthcare (NASDAQ:ALHC) Reaches New 1-Year Low After Insider Selling

Alignment Healthcare, Inc. (NASDAQ:ALHC) reached a new 52-week low during mid-day trading on Wednesday after an insider sold shares in the company. The company traded as low as $9.94 and last traded at $10.37, with a volume of 28545880 shares. The stock had previously closed at $12.94.

Specifically, CEO John Kao sold 27,400 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $13.00, for a total value of $356,200.00. Following the transaction, the chief executive officer owned 590,766 shares of the company’s stock, valued at $7,679,958. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Kao sold 385,270 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $12.68, for a total value of $4,885,223.60. Following the transaction, the chief executive officer owned 1,223,473 shares of the company’s stock, valued at approximately $15,513,637.64. This trade represents a 23.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In related news, CEO John Kao sold 172,600 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $12.96, for a total value of $2,236,896.00. Following the completion of the sale, the chief executive officer directly owned 618,166 shares of the company’s stock, valued at approximately $8,011,431.36. This represents a 21.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analysts Set New Price Targets

Several brokerages have weighed in on ALHC. Raymond James Financial downgraded shares of Alignment Healthcare from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $22.00 to $19.00 in a report on Monday, August 3rd. UBS Group restated a “neutral” rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Alignment Healthcare in a research note on Tuesday, August 4th. JPMorgan Chase & Co. decreased their price target on Alignment Healthcare from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Finally, Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average price target of $23.60.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Some analysts remain constructive after the selloff. Coverage continues to describe ALHC as a potential bargain, while brokerage ratings average “Moderate Buy.” The company’s latest reported quarter also showed revenue growth and an earnings beat, although those results predate the current concerns. Moderate Buy Analyst Rating
• Positive Sentiment: Unusual options activity and bullish analyst commentary suggest some investors are positioning for a rebound following the steep decline. However, these signals are speculative and do not resolve the company’s operating uncertainties. Bullish Analyst Commentary
• Neutral Sentiment: CEO John Kao sold 27,400 shares for approximately $356,200 under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the transaction limits its significance as a direct bearish signal, though his ownership declined by 4.43%. SEC Insider Sale Filing
• Negative Sentiment: Management’s comments at the Baird conference, including limited visibility on Medicare Advantage star ratings, triggered investor concern. Star ratings can influence reimbursement and enrollment, making the lack of clarity a material risk to future growth and profitability. Alignment Healthcare Conference-Related Decline
• Negative Sentiment: Coverage also highlights proposed or potential Medicare Advantage reforms, increasing uncertainty about the company’s reimbursement environment and operating economics. Medicare Advantage Rule Changes
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations following the conference-related selloff. The notices do not establish wrongdoing, but they add potential legal, reputational and financial risk. Securities Fraud Investigation

Alignment Healthcare Stock Performance

The firm’s 50-day moving average price is $15.19 and its 200-day moving average price is $17.75. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.70. The stock has a market cap of $1.80 billion, a P/E ratio of 45.79 and a beta of 1.11.

Alignment Healthcare (NASDAQ:ALHC) last issued its earnings results on Thursday, July 30th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. The firm had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. Alignment Healthcare’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.07 earnings per share. Sell-side analysts expect that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alignment Healthcare

Several large investors have recently made changes to their positions in ALHC. WINTON GROUP Ltd purchased a new stake in shares of Alignment Healthcare in the second quarter worth about $1,164,000. Arizona State Retirement System grew its holdings in Alignment Healthcare by 15.8% during the 2nd quarter. Arizona State Retirement System now owns 53,553 shares of the company’s stock valued at $1,275,000 after buying an additional 7,318 shares in the last quarter. Nykredit A S bought a new stake in Alignment Healthcare in the 2nd quarter worth approximately $36,000. Corient Private Wealth LP raised its holdings in shares of Alignment Healthcare by 128.2% during the 2nd quarter. Corient Private Wealth LP now owns 136,505 shares of the company’s stock worth $3,250,000 after acquiring an additional 76,677 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of Alignment Healthcare during the 2nd quarter worth approximately $755,000. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled healthcare company that provides Medicare Advantage health plans and care-management services for older adults. Through its Alignment Health Plan subsidiary, the company offers insurance coverage designed for Medicare-eligible members, including primary and specialty care coordination, prescription drug benefits, preventive services and access to a network of healthcare providers.

The company combines health-plan operations with proprietary technology intended to support personalized care.